Company Overview and News

 
Bionomics Announces that BNC210 Doesn’t Treat PTSD Symptoms

2018-10-03 biospace
Yesterday, top-line data from Bionomics Limited (ASX:BNO, OTCQX:BNOEF) revealed details of the biopharmaceutical company’s Phase II clinical trial of BNC210 in regards to patients with post-traumatic stress disorder (PTSD). BNC210 is an innovative negative allosteric modulator of the alpha7 nicotinic acetylcholine receptor.
BNO

 
Bionomics begins phase II clinical trial of drug for treating agitation

2018-05-23 proactiveinvestors.com.au
Bionomics Ltd (ASX:BNO) has commenced a phase II clinical trial of its therapeutic candidate, BNC210, in elderly patients with agitation in the hospital setting.
BNO

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

Silicon Investor Message Boards

This table lists all message boards related to ASX:BNO / BIONOMICS LIMITED on message board site Silicon Investor.

FLAME THREAD - Post all obnoxious/derogatory comments here FLAME THREAD - Post all obnoxious/derogatory comments here FLAME THREAD - Post all obnoxious/derogatory comments here WebNode.com - $4B Contract for Next Generation Internet WebNode.com - $4B Contract for Next Generation Internet WebNode.com - $4B Contract for Next Generation Internet
BNO: Benton Oil u0026 Gas Company BNO: Benton Oil u0026 Gas Company BNO: Benton Oil u0026 Gas Company Benton Oil u0026 Gas (BNO) Benton Oil u0026 Gas (BNO) Benton Oil u0026 Gas (BNO)
Save the Webnode3 Save the Webnode3 Save the Webnode3 NGLD- businesswebnow.com NGLD- businesswebnow.com NGLD- businesswebnow.com
Abnormal Volume and Block Trades Abnormal Volume and Block Trades Abnormal Volume and Block Trades Borneo Gold (VSE:BNO) Borneo Gold (VSE:BNO) Borneo Gold (VSE:BNO)
ABNORMAL VOLUME AND BLOCK TRADES ABNORMAL VOLUME AND BLOCK TRADES ABNORMAL VOLUME AND BLOCK TRADES WebNode3 Legal Defense Fund WebNode3 Legal Defense Fund WebNode3 Legal Defense Fund